Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 1463Pancreatic Neoplasms 833Stomach Neoplasms 692Carcinoma, Hepatocellular 647Carcinoma, Non-Small-Cell Lung 542Neoplasms 459Breast Neoplasms 369Ovarian Neoplasms 338Neoplasm Metastasis 337Colonic Neoplasms 332Esophageal Neoplasms 297Liver Neoplasms 266Melanoma 255Lung Neoplasms 246Squamous Cell Carcinoma of Head and Neck 210Cholangiocarcinoma 180Carcinoma, Renal Cell 180Prostatic Neoplasms 175Head and Neck Neoplasms 172Triple Negative Breast Neoplasms 163Rectal Neoplasms 160Endometrial Neoplasms 160Uterine Cervical Neoplasms 155Gastrointestinal Neoplasms 142Urinary Bladder Neoplasms 139Biliary Tract Neoplasms 135Gastrointestinal Stromal Tumors 108Sarcoma 105Esophageal Squamous Cell Carcinoma 102Small Cell Lung Carcinoma 95

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian × Gastrointestinal × Clear all
NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

AstraZeneca

Phase 2 Completed
298 enrolled 18 charts
BreastGastrointestinalGenitourinaryGynecologic

Ovarian

Data powered by HemOnc (CC BY 4.0) Colophon âš¡